<?xml version="1.0"?>
<rss version="0.91">
<channel>
 <title>Industry News -
Drug Discovery World</title>
 <link>http://ddw.net-genie.co.uk</link>
 <description/>
 <language>en</language> 
 <lastBuildDate></lastBuildDate>
 
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409972/first_minister_to_open_biowales_2010.html</link>
 <title>First Minister To Open BioWales 2010</title>
 <pubDate>Wed, 03 Feb 2010 19:51 +0000</pubDate>
 <description><![CDATA[First Minister of Wales Carwyn Jones will open this year’s BioWales, the eighth annual bioscience event at the Vale of Glamorgan Hotel on March 17, just months after being elected leader of the Welsh Assembly Government.  ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409970/aaipharma_services_announces_new_additions.html</link>
 <title>AAIPharma Services Announces New Additions</title>
 <pubDate>Wed, 03 Feb 2010 19:44 +0000</pubDate>
 <description><![CDATA[AAIPharma Services Corporation announced today the addition of Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to its full line of mass spectrometry capabilities.  “This new capability along with our commitment to technological advancement and our rich history of scientific excellence will provide our customers with a tremendous platform to support their drug product development efforts," said L. Lee Karras, CEO.  ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409968/flexion_makes_agreements_with_major_companies.html</link>
 <title>Flexion Makes Agreements With Major Companies</title>
 <pubDate>Wed, 03 Feb 2010 19:32 +0000</pubDate>
 <description><![CDATA[Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.The agreements with AstraZeneca, Merck Serono (a division of Merck KGaA, Darmstadt, Germany) and one other partner establish for Flexion a mature pipeline of clinically enabled drug candidates focused on inflammatory diseases.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409966/proximagen_issues_strategic_update.html</link>
 <title>Proximagen Issues Strategic Update</title>
 <pubDate>Wed, 03 Feb 2010 19:26 +0000</pubDate>
 <description><![CDATA[Since the £50m fundraising in June 2009, the Company has seen a period of unprecedented corporate activity and undergone a notable transition.  During this time, the Company has evolved from specialising mainly in Parkinson’s disease related programmes to the wider area of the CNS in general. The purpose of this announcement is to update shareholders on the progress made since June 2009.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409965/synosia_announces_positive_interim_results.html</link>
 <title>Synosia Announces Positive Interim Results</title>
 <pubDate>Wed, 03 Feb 2010 19:22 +0000</pubDate>
 <description><![CDATA[Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. The Phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 Parkinson’s patients using doses up to 120mg/day for one week. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409964/daiichi_sankyo_submits_new_drug_application.html</link>
 <title>Daiichi Sankyo Submits New Drug Application</title>
 <pubDate>Wed, 03 Feb 2010 19:16 +0000</pubDate>
 <description><![CDATA[Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo), today announced that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare for approval in Japan of CS-8958, a proprietary anti-flu drug. CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409963/peakdale_announce_research_collaboration.html</link>
 <title>Peakdale Announce Research Collaboration</title>
 <pubDate>Wed, 03 Feb 2010 19:11 +0000</pubDate>
 <description><![CDATA[Peakdale Molecular Limited (“Peakdale”), a leading research Services Company headquartered in the UK, announced today that it has entered into an agreement with Pfizer Limited. Peakdale Molecular, through its wholly-owned subsidiary Peakdale Chemistry Services Ltd, will supply custom synthetic chemistry services to Pfizer onsite at the company’s laboratories in Sandwich, UK. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/409962/syrris_establishes_brazilian_subsidiary.html</link>
 <title>Syrris establishes Brazilian subsidiary</title>
 <pubDate>Wed, 03 Feb 2010 19:04 +0000</pubDate>
 <description><![CDATA[Leading chemistry automation product innovator, Syrris established its new Brazilian subsidiary at the beginning of January 2010. With offices on four continents and an expanding distributor network, the new office in São Paulo will enable Syrris to provide efficient and direct support to its rapidly expanding Latin American customer base.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408422/morphosys_licenses_antibody_library_to_shionogi.html</link>
 <title>MorphoSys Licenses Antibody Library to Shionogi</title>
 <pubDate>Mon, 01 Feb 2010 14:08 +0000</pubDate>
 <description><![CDATA[MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Shionogi & Co., Ltd., Osaka, Japan, has elected to expand its current research license to cover the use of MorphoSys's HuCAL PLATINUM technology in drug discovery. <br/><br/>]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408392/aliz_pharma_signs_collaboration_with_lilly.html</link>
 <title>Alizé Pharma Signs Collaboration With Lilly</title>
 <pubDate>Mon, 01 Feb 2010 13:59 +0000</pubDate>
 <description><![CDATA[Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, announced today that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company (NYSE:LLY) regarding Alizé Pharma's AZP-01 program, a program focused on the development of unacylated ghrelin (UAG) agonists for the treatment of type II diabetes.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408391/pharma_funds_cantab_biopharmaceuticals.html</link>
 <title>Pharma Funds Cantab Biopharmaceuticals</title>
 <pubDate>Mon, 01 Feb 2010 13:53 +0000</pubDate>
 <description><![CDATA[Celtic Pharma Holdings Advisors LLP (“CPHA”), today announces it has made significant funding available to Cantab Biopharmaceuticals Limited (“Cantab”) for the development of improved biological medicines or ‘biosuperiors’, via the fund Celtic Pharma Holdings II LP (“CP2”).]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408390/first_patient_dosed_in_hemophilia_b_trial.html</link>
 <title>First Patient Dosed in Hemophilia B Trial</title>
 <pubDate>Mon, 01 Feb 2010 13:49 +0000</pubDate>
 <description><![CDATA[Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies' long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408385/cyntellect_expands_network_across_asia.html</link>
 <title>Cyntellect Expands Network Across Asia</title>
 <pubDate>Mon, 01 Feb 2010 13:39 +0000</pubDate>
 <description><![CDATA[Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, today announces availability of the full Cyntellect product portfolio, including the Celigo™ Adherent Cell Cytometer, the LEAP™ Cell Processing Workstation, and related kits and consumables, to the rapidly expanding life science sector in Asia. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408383/uk_medical_firms_sweep_up_awards_at_arab_health_2010.html</link>
 <title>UK Medical Firms Sweep Up Awards At Arab Health 2010</title>
 <pubDate>Mon, 01 Feb 2010 13:31 +0000</pubDate>
 <description><![CDATA[A London firm improving the quality of life for cancer-sufferers, a Nottingham firm that provides alarms for sleepwalkers and dementia-sufferers, and an Uxbridge firm that allows kidney patients to have dialysis at home are among the UK winners of awards at Arab Health 2010, the largest and most prestigious medical trade fair in the Middle East.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408381/celtic_pharma_polytherics_announce_investment.html</link>
 <title>Celtic Pharma & PolyTherics Announce Investment</title>
 <pubDate>Mon, 01 Feb 2010 13:26 +0000</pubDate>
 <description><![CDATA[Celtic Pharma Holdings Advisors LLP (“CPHA”), the advisor to Celtic Pharma Holdings II LP (“CP2”), together with PolyTherics Limited (“PolyTherics”), innovators in precision engineering of proteins to improve their pharmacokinetic properties, today announce an investment by Leverton Licence Holdings Limited (“LLH”), a wholly-owned subsidiary of CP2, into a research programme to develop a novel biopharmaceutical molecule.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408379/impact_of_nanotechnology_on_life_sciences.html</link>
 <title>Impact Of Nanotechnology On Life Sciences</title>
 <pubDate>Mon, 01 Feb 2010 13:21 +0000</pubDate>
 <description><![CDATA[The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, will again be convening the Nano4Life Conference. Nano4Life 2010, organised by the NanoKTN in collaboration with The Wellcome Trust, will explore the key areas within the life sciences where nanotechnology offers the opportunity to advance healthcare and improve product discovery and development. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408376/bioserve_and_fox_form_strategic_alliance.html</link>
 <title>BioServe and Fox Form Strategic Alliance</title>
 <pubDate>Mon, 01 Feb 2010 13:12 +0000</pubDate>
 <description><![CDATA[BioServe and Fox Chase Cancer Center today announced the formation of an exclusive strategic alliance aimed at easing a bottleneck in oncology research programs. Through this agreement, BioServe will supplement biomaterial from its Global Repository with samples from the prestigious Fox Chase Cancer Center, giving researchers access to an even larger and more dynamic repository of clinical-grade biospecimens.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408366/yorkshire_bank_becomes_corporate_partner_of_biocity.html</link>
 <title>Yorkshire Bank Becomes Corporate Partner of Biocity</title>
 <pubDate>Mon, 01 Feb 2010 13:05 +0000</pubDate>
 <description><![CDATA[Yorkshire Bank is to become a corporate partner of BioCity, the rapidly growing bioscience incubator business park in Nottingham. The bank, which is based in Castle Meadow Road in the city centre, will support the growth of bioscience and healthcare technology companies at BioCity and across the East Midlands by offering financial and business advice services.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408363/labcyte_expands_and_launches_into_new_markets.html</link>
 <title>Labcyte Expands and Launches Into New Markets </title>
 <pubDate>Mon, 01 Feb 2010 13:02 +0000</pubDate>
 <description><![CDATA[Today Labcyte introduced two pre-calibrated liquid class packages for use with its award-winning Echo® acoustic dispensers and POD™ 810 plate assemblers, which move liquids with sound. This expanded capability will allow its high throughput screening customers to not only transfer compounds in DMSO, but enables the transfer of a wide range of liquids necessary to assemble miniaturized assays for biochemical and cell-based screening. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/408324/cygel_sets_zebrafish_screening_method.html</link>
 <title>CyGEL™ Sets Zebrafish Screening Method</title>
 <pubDate>Mon, 01 Feb 2010 12:55 +0000</pubDate>
 <description><![CDATA[The thermo-reversible hydrogel mountant CyGEL™ (Biostatus Ltd., UK) offers a new, simplified method for the micro-injection of zebrafish embryos developed by scientists at the UCD Conway Institute, Dublin.  Live embryos are placed in CyGEL, injected and then gently recovered into embryo medium.  ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/407841/labvantage_announce_training_conference.html</link>
 <title>Labvantage Announce Training Conference</title>
 <pubDate>Sun, 31 Jan 2010 15:31 +0000</pubDate>
 <description><![CDATA[LabVantage today announced that its Customer Training & Education Conference (CTEC) will be held<br/>from April 18 to 22, 2010, at Disney's Grand Floridian Resort, Orlando, Florida. <br/><br/>]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/407839/exome_sequencing_of_a_three_generation_family.html</link>
 <title>Exome Sequencing of a Three Generation Family</title>
 <pubDate>Sun, 31 Jan 2010 15:18 +0000</pubDate>
 <description><![CDATA[Researchers from University of Miami Miller School of Medicine and Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) have recently published a research study on human exome resequencing results from eight individuals that span across three generations of a family. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/407838/domainex_and_pharmidex_announce_alliance.html</link>
 <title>Domainex and Pharmidex announce alliance</title>
 <pubDate>Sun, 31 Jan 2010 15:14 +0000</pubDate>
 <description><![CDATA[Domainex Ltd and Pharmidex announced today the formation of a strategic alliance, combining their expertise and innovative technologies to provide the market with an integrated, high-quality drug discovery services platform.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/403789/sygnature_chemical_services_strengthens_scientific_team.html</link>
 <title>Sygnature Chemical Services Strengthens Scientific Team</title>
 <pubDate>Sun, 24 Jan 2010 16:29 +0000</pubDate>
 <description><![CDATA[Sygnature Chemical Services Ltd., a leading UK-based provider of premium discovery chemistry services to the global pharmaceutical industry, today announced the appointment of Dr Michael (“Mick”) Knaggs as Head of Computational Chemistry.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/403787/tap_appoints_new_commercial_director.html</link>
 <title>TAP Appoints New Commercial Director</title>
 <pubDate>Sun, 24 Jan 2010 16:22 +0000</pubDate>
 <description><![CDATA[The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, today announced the appointment of Phillip Sefton as its new Commercial Director. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/403785/new_merck4biosciences_website_launched.html</link>
 <title>New Merck4Biosciences website launched</title>
 <pubDate>Sun, 24 Jan 2010 16:15 +0000</pubDate>
 <description><![CDATA[Customers of Merck’s European Biosciences business, which includes the brands Calbiochem®, Novabiochem® and Novagen®, are now benefiting from a newly launched web platform, which offers: standard European pricing, access to 10 000 high quality products, responsive customer service, industry leading technical support and comprehensive technical documentation.]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/401622/rexahn_granted_patent_for_anticancer_compound.html</link>
 <title>Rexahn Granted Patent for Anti-cancer Compound</title>
 <pubDate>Wed, 20 Jan 2010 14:45 +0000</pubDate>
 <description><![CDATA[Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117. ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/400966/bioinformatics_llcs_newest_report.html</link>
 <title>Bioinformatics LLC's Newest Report</title>
 <pubDate>Tue, 19 Jan 2010 14:30 +0000</pubDate>
 <description><![CDATA[BioInformatics, LLC announces the pending release of its newest report, The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliers. <br/>]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/400965/regenerative_medicine_to_receive_45_million_funding.html</link>
 <title>Regenerative Medicine To Receive £4.5 Million Funding</title>
 <pubDate>Tue, 19 Jan 2010 14:26 +0000</pubDate>
 <description><![CDATA[Over 40 British companies are to receive more than £4.5 million from the Technology Strategy Board to support research and development into regenerative medicines. The first part of a major £21.5 million research and development investment programme in regenerative medicines, support will be provided for 30 commercial feasibility projects in the area of regenerative medicine therapies.  ]]></description>
</item>
 
 <item>
 <link>http://ddw.net-genie.co.uk/industrynews/400957/quotient_extends_agreement_to_cardiff_transfer.html</link>
 <title>Quotient Extends Agreement To Cardiff Transfer</title>
 <pubDate>Tue, 19 Jan 2010 14:08 +0000</pubDate>
 <description><![CDATA[An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed.  ]]></description>
</item>
 </channel>
</rss>